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Background: Combinations of Fluorouracil (FU) and biomodulator Leucovorin (LV) established as a standard regimen for therapy of colorectal cancer with metastases. To give better antitumor activity in colorectal 
cancer therapy, oxaliplatin is combined with FU/LV and give significant improvement. Fluorouracil can only be given by intravenous administration. 
This limitation raised effort to find alternative drugs that can be given orally, such as capecitabine. Capecitabine is an oral FU prodrug, with high oral bioavailability, highly accumulated in neoplastic tissue to be converted in FU, and well tolerated. Some clinical studies revealed effectivity of capecitabine plus oxaliplatin (XELOX) compared to FU/LV plus oxaliplatin (FOLFOX). 
Objective: This article is aimed to compare non inferiority of XELOX to FOLFOX in colorectal cancer with metastases, viewed form primary outcomes and secondary outcomes. 
Results:  XELOX was comparable to FOLFOX with some benefitsover FOLFOX.
Conclusion:  XELOX could be considered as FOLFOX replacement as a standard therapyfor colorectal cancer with metastases. 
Latar Belakang:  Sampai saat ini, terapi untuk kanker kolorektal masih didominasi oleh penggunaan 
fluorouracil (FU) yang dikombinasi dengan biomodulator leucovorin (LV). Penggunaan FU/LV seringkali 
dikombinasikan dengan oxaliplatinuntuk meningkatkan aktivitas antitumornya serta mencegah metastasis. 
Keterbatasan FU adalah hanya bisa diberikan secara intravena sehingga menyebabkan digalinya alternatif 
obat secara oral, salah satunya capecitabine. Capecitabine adalah prodrug bagi FU yang mempunyai 
bioavailabilitas oral tinggi, terkonsentrasi dalam jumlah besar dalam jaringan tumor untuk dikonversi 
menjadi FU, serta dapat ditoleransi dengan baik. Beberapa penelitian klinis telah menguji efektivitas 
penggunaan capecitabine plus oxaliplatin (XELOX) dibandingkan FU/LV plus oxaliplatin (FOLFOX).
Tujuan:  Tulisan ini bertujuan untuk membandingkan efek penggunaan kombinasi XELOX dibandingkan 
FOLFOX dalam terapi kanker kolorektal dengan metastasis yang ditinjau dari beberapa penelitian klinis, 
dengan melihat outcome primer dan sekundernya. 
Hasil: Hasil menunjukkan bahwa penggunaan XELOX non inferior dari FOLFOX pada kanker kolorektal 
dengan metastasis, yang dilihat darioutcome primer dan outcome sekunder, serta memberikan beberapa 
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kelebihan dibandingkan dengan FOLFOX
Kesimpulan: XELOX dapat dipertimbangkan 
sebagai regimen pengganti FOLFOX untuk terapi 
kanker kolorektal dengan metastasis.
BACKGROUNDColorectal cancer is a malignancy with a high incidence rate, in which there are approximately one million new patients each year, and 33% of them resulted in death.1 Within the last few decades, the treatment of metastatic colorectal 
cancer was dominated by fluorouracil (FU), a 
fluoropyrimidine anti-cancer, which since it was introduced in 1957, is still considered the drug of choice because it has been proven effective and capable of improving patient outcome.2 This medicine could not be given orally because it would be damaged severely by the hepar,3 hence it is given as intravenousprolonged infusion combined with leucovorin (LV) biomodulator.4Some randomized control trial showed 
that the administration of fluoropyrimidine 
anti-cancer drugs (such as : fluorouracil/FU) combined with pre-operative radiation were able to improve local tumor condition, but were not able to prevent metastases.5 This becomes the based of oxaliplatin utilization, a platinum anti-cancer analog, in combination with FU. Just as its predecessor, cisplatin, oxaliplatin works by producing covalent bond between platinum with guanine and adenine in cell DNA, altering replication and transcription process of the DNA. Oxaliplatin is more preferred than cisplatin because it is more concentrated in colon cancer cells.6Oxaliplatin works especially by inducing apoptosis, not only p53-independent pathway which would go through ERK signaling, but also p53-dependent  pathway which involve the role of p53 up-regulate modulator of apoptosis (PUMA),7 or by increasing the concentration of phospho-p53 and p53 total protein.8 Compare to cisplatin and carboplantin, oxaliplatin cause less side effects for the kidneys and bone marrow, while its main side effect is sensoric neuropathy.9Oxaliplatin combined with FU/LV for colorectal cancer has been proven capable of 
increasing response rates and time to disease 
progression (TTP) significantly compare to the combination of FU/LV alone. A meta-analysis showed that the addition of weekly oxaliplatin as neoadjuvant to FU/LV in colorectal cancer are able to improve partial complete response (pCR) and reduce intra-abdominal as well as peri-operative. In addition to that, even though this combination cause more G3/4 side effects, but this does not require further operative treatment and reduce mortality- 60 days post-operative.5The impracticality of FU initiates a search of 
alternative fluoropyrimidine that can be given orally, leading to the invention of capecitabine, which was designed to be able to deposition its active compound in tumor location and not in healthy non-tumor tissues.4 Capecitabine as an alternative of FU, was developed to improve non-tumor tolerability and toxicity. It is a prodrug of FU, which would be converted into FU both in healthy and tumor tissues by enzyme thymidine phosphorylase (TP), that is contained more 
in tumor tissues. Hence, drug specificity for tumor becomes higher and reduce systemic side effects.2Capecitabine could be given orally with high predicted bioavailability and could be well-tolerated. A few studies showed that capecitabine was more active than intravenous FU/LV for inducing objective tumor response.10 
Except being used as the first line in the treatment of metastatic colorectal cancer, capecitabine could also be used as adjuvant therapy for late stage colon cancer.11A phase I clinical trial showed that the combination of capecitabine and oxaliplatin (XELOX) with the recommended dose of intravenous oxaliplatin 130 mg/m2 on day 1, continued with capecitabine 1.000 mg/m2 twice daily for 14 days in 3 weekly cycles, were not only easy to administer but also has a promising antitumor effect.12 Currently, XELOX are used for treatment in late stage and metastatic colorectal 
cancer, both as first and second line treatment, with similar effectivity as FU and oxaliplatin combination (FOLFOX).11Intraoral Fluoropyrimidine would provide 
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more comfort for patients and medical personnels. If terapeutic outcome of both XELOX and FOLFOX are similar, then orally administered drugs would provide more ease and comfort. Hence, an analysis needs to be done to review some recent Randomised Controlled Trial/RCT regarding the use of XELOX and FOLFOX for the treatment of metastatic colorectal cancer to 
determine the effectivity of oral fluoropirimidin when compared to intravenous administration by examining terapeutical outcome and side effects. 
SEARCHING AND SELECTION METHODS OF 
ARTICLESThis article review did not use systematic method while searching for medical journals. Instead, it used randomized search by Google® search engine (www.google.co.id). There were 6 (six) randomised controlled trial publication that compare the combination of capecitabine plus oxaliplatin (XELOX) and FU plus oxaliplatin (FOLFOX) in the treatment of metastatic 
colorectal cancer. In which five studies 12,13,14,15,16 were phase III RCT, while one study10 was phase II RCT.
Inclusion criteriaThis study included randomised controlled trial research that compare the combination of oxaliplatin plus capecitabine and oxaliplatin plus FU/LV or FU in the treatment of metastatic colorectal cancer. Study subjects should be at least 18 years of age, histologically diagnosed with cancer lession that could not be resected, had more than 3 months life expectancy, and had adequate bone, liver, and kidney function. Subjects were excluded if they had history of neuropathy, had been treated with oxaliplatin within less than 6 months before research started, or had severe heart disorder, hypertension, and myocardial infarct, as well as pregnancy.
EvaluationEvery studies did preliminary assessment which included medical record, physical examination, thorax xray, electrocardiography, carcino embryonic antigen (CEA), blood test 
(haematology and biochemistry) that varies between 1-4 weeks before intervention, but there was one research that did not mention the period of which they did the initial assessment. Response to therapy were evaluated using Response Evaluation Criteria in Solid Tumors 
Group (RECIST), to define the entire resonse after subjects had been treated for at least 4 weeks. Evaluation was done by the researchers and or independent review committee. Observation of post-research response was done every 12 weeks (3 months), until there was disease progression or death. The evaluation of toxicity and side effeccts was done during therapy and until 28 days after the last dose, in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 guideline 13,14,15,16; according to Common Toxicity Criteria v2.0,10 while one research did not mention which guideline it used.12 One research15 also assessed patients quality of life (using the EORTC QLQ-C30 and FACIT Chemotherapy convenience and 
satisfication questionnaire on therapy guideline) and the utilization of health resources.
Statistical AnalysisArticles contained at least one outcome that was observed, which was overall response rate (ORR), overall survival (OS), progression-free survival (PFS), time to response, median duration of response, time to treatment failure (TTF), safety, and one study16 assessed one additional parameter which was rate to radical surgery (RRS). 
Overall response rate (ORR) was defined as the proportion of patients who experience complete response and partial response. While stable disease was not included into ORR category, eventhough later it could be counted on tumor control rate. The non-inferior margin was when the difference of ORR between XELOX and FOLFOX group less than 15%. Progression-
free survival(PFS) was defined as the amount of time between the start of treatment until disease progression, despite the objective response (ORR). It was measured with Kaplan-
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Meier method. Median overall survival (OS) was 
defined as the amount of time between the start of treatment until patient’s death of any cause. This was also measured with Kaplan-Meier method.
Median time to failure (TTF) was defined as the amount of time between the start of treatment until drug withdrawal, either due to toxicity, disease progression, or death of any 
cause. Median duration of response was define 
as the amount of time between the first recorded response until disease progression or death. Analysis survival (PFS, OS, median duration of response, median TTF) was done using Cox proportional hazards model and Kaplan-Meier estimation13,14,15 to provide relative Hazard Ratio (HR) with 95%14,15 and 97,5%13 CI of XELOX group compare to FOLFOX. Rate to radical 
surgery was defined as the proportion of patients undergoing surgery to remove primary tumor or its metastases as curative measure after therapy during research period. 
RESULTSThere were 6 (six) articles for review. All articles had met inclusion criteria, in which each article’s characteristic was described in Attachment 1 Table 1. The resuts of the entire outcome evaluation can be seen in Attachment 2 Table 2, while side effects and toxicity was described in Attachment 3 Table 3.
Patient demography The basic characteristic of patients on XELOX and FOLFOX group were all proportional in all clinical trial (Table 1). For performance status, several different parameters were used, such as 
Karnosfky Performance Status (PFS) > 70,  or Eastern Cooperative Oncology Group (ECOG) < 2, or WHO performance 0-2. Most subjects had KFS 
index > 70 (median 90),  ECOG score 0 and 1, and WHO score 2.  All six studies mentioned exclusion criteria which include pregnant woman, kidney and severe heart disorder, brain metastases; two studies15,16 exclude patients with history of previous oxiplatin treatment, patients who were a candidate for liver metastasectomy after 
chemotherapy, and patients with cardiovascular diseases (hypertension, angina pectoris, and myocardial infarct). On one of the studies,12 patients with previous history of adjuvant cemotherapy were found more in XELOX group (26%) compare to FOLFOX group (16%) 
(p=0,032). One research classified patients based on their creatinine clearance to analyze the side effects and toxicity of treatment, based on the 
value of creatinine clearance > 80 mL/minute and 50-80 mL/minute.16One of the studies delayed treatment before completing six cycles, in which treatment delay were found more in FOLFOX group (37,7%) compare to XELOX group (27,8%). Most delay in both groups were caused by disease progression and toxicity, which were 23% of total patients (this would be adressed further in side effects and toxicity section).10
Drugs AdministrationXELOX combination was administered by giving oxaliplatin 130 mg/m2 through IV drips for 2 hours on day 1, continued with oral capecitabine 1000 mg/m2, twice daily  for 2 weeks, in 3 weeks cycle. While FOLFOX combination was administered by giving oxaliplatin 85 mg/m2 IV drips for 2 hours on day 1 continued with LV 200 mg/m2 IV drips for 2 hours, and then continued with FU 400 mg IV injection and FU 600 mg/m2 IV drips for 22 hours for 2 days straight, in 2 weeks cycle. 
Outcome
Overall Response Rate (ORR)The evaluation of ORR was done on all studies, and was made as the primary outcome in one of the studies10, and as secondary outcome 
in the other five studies.12,13,14,15,16  The lowest percentage of ORR was 20% in XELOX group and 18% in FOLFOX group,14 while the highest was 51% in  XELOX group and 57% in FOLFOX group.16 The ORR value on the other five 
studies was between 37-48%. In five of the studies,12,13,14,15,16 it was found that there were 
no statistically significant difference of ORR value between XELOX dan FOLFOX group. 
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Overall Survival (OS)
Measurement of OS was done in five studies, where XELOX group had OS between 11,9 – 19,9 months, while FOLFOX group had OS between 12,6 – 20,8 months. On all of the studies, it was 
found that there was no statistically significant difference of OS between the groups. 
Progression-Free Survival (PFS) and Time 
to Progression (TTP)
PFS  values that was found in all five studies varied. In which the PFS value of XELOX group was between 4,7-8,9 months, while in FOLFOX group it was 4,8-9,5 months. There were no 
statistically significant difference of PFS values between the groups (XELOX and FOLFOX).
Median duration of responseThe median value in four of the studies was between 5,6-10,1 months in XELOX group and 6,2-9,4 months in FOLFOX group.12,13,14,15 Statistically, median duration of response in four 
of the studies showed no significant difference.
Median time to treatment failure(TTF)This parameter was found in four of the studies. Results varied between 4,1-6,1 months for XELOX group and 4,0-6,9 months for FOLFOX group.12,13,14,15,16 Ib line with other outcome 
parameter, there was no statisticqally significant difference of TTF median between the groups. 
Rate to radical surgery (RRS)There were two research that measured RRS.15,16 Radical surgery that was done include liver metastasectomy, lung metastasectomy, primary tumor resection, and other part resection. One study showed that the RSS for XELOX group was lower (3,5%) compare to FOLFOX group (6,5%) with OR 1,96 (95% CI 1,18-3,23).16 While the other research only describe the number of patients who undergo radical surgeries, in which there were 30 patients (19,2%) in XELOX group and 34 patients (22,6%) in FOLFOX group, without further analysis.15 According to this results, it could be concluded that radical surgery was found more in FOLFOX 
group compare to XELOX group. 
Safety and ToxicityGenerally, side effects of all toxicity  was found more in FOLFOX group compare to XELOX group, except in one of the studies.10  Mielotoxicity in the form of anemia and neutropenia was found more in FOLFOX group compare to XELOX group, but thrombocytopenia was found more in XELOX group.15  The mielotoxicity found in these studies varied from very mild10 or even death.12 Neutropenia G4 that was found twice larger in FOLFOX group compare to XELOX group13 presumed to contribute in initiating the occurence of more G4 side effects in FOLFOX group compare to XELOX group which was 25% vs. 12% 13 and 65% vs. 50%.14Non hematology toxicity that was found the most is neurotoxicity, in which G3 neurotoxicity was found more in XELOX group compare to FOLFOX group (24,5% vs. 18,5%), eventhough this number was not statistically different in both groups.10 Neurological toxicity was also one of the reason of treatment discontinuation12,13 eventhough it did not cause death. The incidence of stomatitis between FOLFOX group and XELOX group was also statistically different (25,9% vs. 13,1%).10 Stomatitis contributed to treatment discontinuation due to toxicity10 and in one of the pationt of XELOX group was found stomatitis, neutropenia, and thrombocytopenia as the cause of death.12 Apart of stomatitis, treatment delay and discontinuation happened due to a lot of causes, like:  neurological toxicity and oxaliplatin intolerance,12 diarrhea,13 in addition to that the presentation of treatment discontinuation was 27% in both groups.12Gastrointestinal symptoms in FOLFOX and XELOX group were quite varied, but hand-foot syndrome was found more in XELOX group.12,13,14,15,16 One interesting founding was the increase of G3 nausea, diarrhea, and thrombocytopenia in XELOX group in patients with creatinine clearance 50-80 mL/minute 
compare to patients with creatinine clearance > 80 mL/minutes; likewise, dosage delay was also 
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found more in patients with lower creatinine clearance. While in FOLFOX group, no side effect difference was found between patients with 
creatine clearance 50-80 mL/minutes and >80 mL/minute.16Generally, aside from the complications of side effects10,12 patients cause of death was also due to disease progressivity.15 The result of treatment-related mortality analysis of both 
groups showed no significant difference13,16 while another research found 2,1% (14 patients) for XELOX group and 1,7% (11 patients) for FOLFOX group.12All-cause 60-day mortality was 4% in both groups13 while another research found difference in FOLFOX compare to XELOX group, which was 4,2% vs. 2,1%15 and 3,4% vs 2,3%.12
DISCUSSIONOxaliplatin and capecitabine combination had been researched a lot and had been approved as anti-cancer treatment in metastatic colorectal cancer. The clinical activity of XELOX combination was based on preclinical datas that found capecitabine and oxaliplatin has supra-additive effect. This combination was able to inhibit in vivo growth of CXF280 colon cancer cells more effectively than othe use of single drug. Oxaliplatin was able to upregulate TP enzyme 
that was spesific for FU inside CXF280 cancer cells. This TP upregulation by oxaliplatin was the one that produced supra-additive activity in XELOX, that could not be found in FOLFOX intravenous drips combination.4
All five phase III RCT research had been 
able to finish multicenter research for this high epidemiology cancer. Because the objective of the research was to assess the noninferiority of XELOX combination compare to FOLFOX 
(that has been accepted as first line treatment for metastatic colorectal cancer), hence the non-inferiority of XELOX compare to FOLFOX combination in the treatment of metastatic colorectal cancer was the main concern of the research.
Research outcomeIn this article review, one research10 was 
not being used to make definitive comparation between researched drugs and standard drugs, because this research was a phase II clinical trial, 
that aimed to determine the efficacy of the drugs. Nevertheless, this research was able to show that XELOX combination had 43,5% response rate (95% CI 31,0%-56,7%), with 9 months TTP (95% CI 8-10 bulan) as well as symptoms relieved in almost 50% patients with asthenia, anorexia, pain and low KPS index on baseline. This research supported the reccomendation to exchange pviFU with capecitabine, because orally administered medicine was proven to be able to decrease intravenous catheter side effects, such as infection, thrombosis, displacement risk, and personal discomfort.10The results of the other four phase III clinical trial, showed that treatment outcome between XELOX and FOLFOX was relatively comparable, as seen in p value, OR, or HR of each outcome in both groups. ORR or PFS value as primary outcome of the research showed difference in noninferiority margin, hence it could be concluded that XELOX combination was non inferior from FOLFOX combination. As well as secondary outcome (OS, median duration of response, and median TTF) for all 
research showed no statistically significant difference. Except for RRS, which showed that FOLFOX group had twice higher rate  of radical surgeries compare to XELOX group, however the cause of this was not analyzed. Hence, it could be said that in terms of outcome,  XELOX combination was comparable to FOLFOX combination. Even in term of post-therapy radical surgeries, XELOX combination showed more advantages compare to FOLFOX.15,16 In terms of side effects and toxicity, XELOX and FOLFOX combination was comparable. The 
interesting finding was that the occurence of G3/4 neutropenia was found relatively lower in XELOX group compare to FOLFOX, except in one research in which the result of neutropenia was 25% higher in XELOX group. However, this research did not mentioned any possible causes.10
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Drug Administration Technique and 
Treatment CycleThe administration of XELOX combination is mainly via oral for capecitabine and intravenous drips for oxaliplatin given in 2 hours with 3 weeks cycle; while FOLFOX combination needed 48 hours of intravenous catether (2 days straight) because the administration of FU or FU/LV and oxaliplatin should be given intravenously in 2 weeks cycle. From the perspective of patients comfort and visit frequencies, XELOX combination is more advantegous because the time needed for one dosage administration is shorter and the frequencies of hospital visits is less often (rest period of every cycle is longer). In addition to that, capecitabine could be given orally, hence it reduced the risk of complication in intravenous catheter administration compare to FU or FU/LV. It could be seen from the frequencies of hospital visits, central venous access, and the time needed for drugs administration is shorter in XELOX combination compare to FOLFOX combination. From this perspective, XELOX combination is more superior than FOLFOX combination. Nevertheless, further statistical analysis is needed.In terms of comfort, XELOX combination provides more comfort for both patients and care giver. XELOX combination allows patients to only come to health facilities every 3 weeks for only 2 hours during oxaliplatin intravenous drips. Colorectal cancer patients who were given paliative care with FU/LV, would have uncomfortable treatment schedule that would severely reduce their resting period. In addition to that, patients are at larger risk of infection due to intravenous catheter insertion.4 Another factor that affect patients comfort is that the 3 weeks cycle in the administration of oxaliplatin in XELOX combination (compare to 2 weeks cycle in FOLFOX combination), and the fact that capecitabine could be given orally.11 Hence, XELOX combination contibutes heavily in terms of patients condition and autonomy.4All six published research did not analyze 
the financial effectivity of XELOX combination 
compare to FOLFOX combination. However, there are two studies which found that XELOX 
combination were more financially effective 
compare to FOLFOX combination. This financial advantages could happen due to direct or indirect causes, for instance : social cost that patients and their families would suffer while they were hospitalized for longer period.17,18
CONCLUSSIONThe utilization of XELOX combination is non-inferior compare to FOLFOX combination that can be concluded from primary outcome (according to the value of Odds Ratio, Hazard Ratio, and Progression Free Survival) and secondary outcome (Overall Survival, median duration of response, and median Progression Free Survival), even in terms of Response Rate to Surgery, XELOX combination is better than FOLFOX combination. XELOX combination is also better in terms of patients comfort especially regarding drugs administration technique because it could be given orally, hence it could avoid intravenous administration complication. Also in terms of treatment cycle, in which the period for drugs administration is shorter in XELOX combination with longer resting period, hence reducing the frequencies of hospital visits. Financially speaking, XELOX combination is more cost-effective compare to FOLFOX combination.
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Regime
n 
FOLFO
X: oxal
iplatin 
130 mg
/m2 in
fusion 
fo
r 
2 
ho
ur
 o
n 
fi
rs
t d
ay
  
and FU
 protra
cted 
venous
 infusio
n 250 
mg/m2
/day fo
r 1-21 
days
XELOX
: Capec
itabine
 
1.000 m
g/m2, 
2 
times p
er day 
, 14 
days pl
us oxal
iplatin 
i.v 130
 mg/m
2, on 
fi
rs
t d
ay
 e
ve
ry
 3
 
weeks 
cycles
XELOX
: oxalip
latin 13
0 
mg/m2
 for 2 h
ours on
 
fi
rs
t d
ay
 o
ne
 c
on
ti
nu
ed
 
with ca
pecitab
ine ora
l 
1000 m
g/m2, 
2 times
 
per day
 , 2 wee
ks ever
y 
3 week
s
XELOX
: oxalip
latin 
infusio
n 130 m
g/m2 
for 2 ho
urs on 
1st day
 
and cap
ecitabi
ne 100
0 
mg/m2
, two ti
mes 
perday
, 2 wee
ks, eve
ry 
3 week
s
XELOX
: oxalip
latin 
infusio
n 130 m
g/m2 
fo
r 
2 
ho
ur
s 
on
 fi
rs
t 
day, co
ntinued
 with 
capecit
abine o
ral 
100 mg
/m2 2 
times 
perday
, 2 wee
ks, 
every 3
 weeks
XELOX
 : Oxali
platin 
130 mg
/m2 i.v
 for 
2 
ho
ur
s 
on
 fi
rs
t 
day, co
ntinued
 with 
capecit
abine 1
000 mg
/
m2, 2 t
imes p
erday, 2
 
weeks,
 every 
3 week
s
XELOX
: xalipl
atin 13
0 
mg/m2
 for 2ho
urs 
in day 
1 conti
nued 
with ca
pecitab
ine 
oral 10
00 mg/
m2, 2x
 
daily, 2
 weeks
 every 
3 
weeks
FOLFO
X: FU 2
.250 
mg/m2
 for 48 
hours 
in day 
1, 8, 15
, 22, 
29, and
 36, plu
s 
oxalipl
atin 85
 mg/
m2 in d
ay 1, 15
, and 
29, eve
ry 6 we
eks
FOLFO
X: LV 2
00 mg/
m2 IV i
nfusion
 for 2 
hours c
ontinu
ed with
 
FU 400
 mg/m
2 IV an
d 
FU 600
 mg/m
2 infus
ion 
for 22 h
ours, tw
o days 
straigh
t every
 2 weee
ks, 
in addi
tion to 
oxalipl
atin 
85 mg/
m2 infu
sion fo
r 2 
hours i
n day 1
FOLFO
X:  LV 2
00 mg/
m2 IV i
nfusion
 for 2 
hours c
ontinu
ed with
 
FU 400
 mg/m
2 IV 
and FU
 600 m
g/m2 
infusio
n for 22
 hours,
 
two da
ys stra
ight ev
ery 
2 weee
ks, in a
ddition
 
to oxal
iplatin 
85 mg/
m2 infu
sion fo
r 2 
hours i
n day 1
FOLFO
X: oxal
iplatin 
100 mg
/m2inf
usion 
for 2 ho
urs con
tinued 
with LV
 400 m
g/
m2 infu
sion th
en 
i.v inje
ction o
f FU 
400 mg
/m2 an
d FU 
2.400-3
000 mg
/m2 
contino
us infu
sion 
for 46 h
ours ev
ery 2 
weeks
FOLFO
X: LV 1
75 or 
350 mg
 i.v eve
ry 2 
weeks 
in addi
tion to 
oxalipl
atin 85
 mg/
m2 for
 2 hour
s in day
 
1 conti
nued w
ith FU 
400 mg
/m2 i.v
 and FU
 
2400 m
g/m2 i
nfusion
 
for 46 h
ours
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Subject
s 
selectio
n criter
iaPa
si
en
t a
ge
 >
18
 
ye
ar
s 
ol
d,
  c
on
fi
rm
ed
 
histolo
gicaly o
f 
colorec
tal can
cer, 
K
ar
no
fs
ky
  s
ta
tu
s 
 >
 
70
, l
if
e 
ex
pe
ct
an
cy
 >
 
3 
m
on
th
s,
 fi
ni
sh
ed
 
previou
s adjuv
ant 
treatm
ent for
 at leat
s 
6 
m
on
th
s,
 H
b 
> 
10
 
g/
dL
, n
eu
tr
op
hi
l >
 
2000/m
m3, pla
telet 
co
un
t >
 1
00
.0
00
/m
m
3,
 
serum 
creatin
ine < 
1,2 mg
/dL, cr
eatinin
e 
cl
ea
ra
nc
e 
> 
55
m
L/
minute
s, biliru
bin and
 
serum 
transam
inase <
 
3x norm
al
Outpat
ient, 
ag
e 
>1
8 
ye
ar
s 
ol
d,
   
co
nf
ir
m
ed
 
histolo
gicaly o
f 
colorec
tal can
cer, 
K
ar
no
fs
ky
  s
ta
tu
s 
 >
 
70, life
 expect
ancy 
> 
3 
m
on
th
s 
, h
ad
 
minimu
m one 
lession
 accord
ing to 
Respon
se Eval
uation 
Criteria
 in Soli
d 
Tumor
s Group
 
Criteria
, if had
 
previou
s histor
y of  
FU che
mother
apy 
sh
ou
ld
 a
t l
ea
st
  >
 1
 
year be
fore re
search
 
period
O
ut
pa
ti
en
t, 
ag
e 
>1
8 
ye
ar
s 
old , Ea
stern C
oopera
tive 
Oncolo
gy Grou
p (ECO
G)
status 
 < 2 life
 expect
ancy  
> 
3 
m
on
th
s,
 w
it
ho
ut
 
history
 of chem
othera
py 
for adv
ance di
seases,
 
radioth
erapy o
r surgi
cal 
terapy 
for met
astases
 
ha
d 
be
en
 fi
ni
sh
ed
 
for at le
ast  4 m
onths 
before 
researc
h perio
d,  
adequa
te hem
atologi
cal, 
liver, an
d kidne
y funct
ion, 
not cur
rently p
regnan
tO
ut
pa
ti
en
t, 
ag
e 
>1
8 
years o
ld , Eas
tern 
Cooper
ative O
ncolog
y 
Group 
(ECOG)
status 
 
< 2, life
 expect
ancy  
> 
3 
m
on
th
s,
 h
ad
 
minimu
m one 
lession
 
w
it
h 
di
am
et
er
 >
 2
0 
mm me
asured
 by 
CT
 s
ca
n 
or
  >
 1
0 
m
m
 
by MRI
 adequ
ate 
hemato
logical,
 liver, 
and kid
ney fun
ction, 
not cur
rently p
regnan
tPas
ie
nt
 a
ge
 >
18
 
ye
ar
s 
ol
d,
  c
on
fi
rm
ed
 
histolo
gicaly o
f 
colorec
tal can
cer 
(R
E
CI
ST
 c
ri
te
ri
a 
> 
1),  ECO
G score
 < 2,   
lif
e 
ex
pe
ct
an
cy
  >
 3
 
month
s   adeq
uate 
hemato
logical,
 liver, 
and kid
ney fun
ction, 
not cur
rently 
pregna
nt l, no
 
heart d
isorder
 or 
neurop
athy
Pa
si
en
t a
ge
 >
18
 y
ea
rs
 
old , ha
d meta
static  
or adva
nced  
adenoc
arsinom
a 
colorec
tal, tno
 history
 
of chem
othera
py for 
advanc
e disea
ses, 
WHO p
erform
ance 
status(
PS) 0-2
, 
adequa
te bone
 
marrow
, liver a
nd 
kidney
 functio
n
Numbe
r of 
subject
s in eac
h 
group
FOLFO
X: 56
XELOX
: 62
XELOX
 : 171
FOLFO
X: 171
XELOX
: 1017
FOLFO
X: 1017
XELOX
: 313
FOLFO
X: 314
XELOX
: 156
FOLFO
X: 150
XELOX
: 1575
FOLFO
X: 822
Male su
bjects
FOLFO
X : 28 (
50%)
XELOX
 : 33 (5
43,2%)
XELOX
 : 107 (
63%)
FOLFO
X: 100 
(58%)
XELOX
: 612 (6
0,2%)
FOLFO
X: 595 
(58,5%
)
XELOX
: 194 (6
2%)
FOLFO
X:191 (
61%)
XELOX
: 100 (6
4%)
FOLFO
X: 90 (6
0%)
XELOX
: 1039 
(66%)
FOLFO
X: 537 
(64%)
Median
 of age 
(range
)
FOLFO
X : 64 (
41-79)
XELOX
 : 67 (2
5-79)
XELOX
 : 64 (3
2-80)
FOLFO
X: 65 (3
5-81)
XELOX
: 61 (24
-84)
FOLFO
X: 62 (2
4-83)
XELOX
: 60,7 (
26-81)
FOLFO
X: 59,7
 (26-83
)XE
LOX: 66
 (32-83
)
FOLFO
X: 64 (4
2-84)
XELOX
: 64 (57
-70)
FOLFO
X: 63 (5
7-69)
Locatio
n of pr
imary t
umor
•  Colon
FOLFO
X : 51 (
82,3%)
XELOX
 : 46 (8
2,1%)
XELOX
 : 110 (
64%)
FOLFO
X: 116 
(68%)
XELOX
: 673 (6
6,2%) 
FOLFO
X: 655 
(64,4%
)
XELOX
: 185 (5
9%)
FOLFO
X: 201 
(64%)
XELOX
: 94 (60
%)
FOLFO
X: 95 (6
3%)
XELOX
: 843 (5
3%)
FOLFO
X: 465 
(57%)
•  Rectu
m
FOLFO
X : 11 (
17,7%)
XELOX
: 10 (17
,9%)
XELOX
 : 49 (2
9%)
FOLFO
X: 49 (2
9%)
XELOX
: 252 (2
4,8%)
FOLFO
X: 292 
(28,8%
)
XELOX
: 102 (3
2%)
FOLFO
X: 89 (2
8%)
XELOX
: 37 (24
%)
FOLFO
X: 38 (2
5%)
XELOX
: 497 (3
2%)
FOLFO
X: 247 
(30%)
•  Both
NA
XELOX
 : 12 (7
%)
FOLFO
X: 6 (3%
)X
ELOX: 
92 (9%
)
FOLFO
X: 70 (6
,8%)
XELOX
: 26 (8%
)
FOLFO
X: 24 (8
%)
XELOX
: 25 (16
%)
FOLFO
X: 17 (1
1)
NA
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Primar
y outco
me O
RR
TTP (P
FS)
PFS
PFS
ORR
PFS
Second
ary 
outcom
e 
TTP (P
FS), tox
icity
ORR, S
afety, 
respon
se rate
, TTF, 
OS, dur
ation o
f 
respon
se
OS, OR
R, dura
tion of 
respon
se, TTF
, safety
OS, OR
R, time
 to 
respon
se, dur
ation o
f 
respon
se, TTF
, safety
PFS, OS
, time t
o 
respon
se, dur
ation o
f 
respon
se,safe
ty
OS, OR
R, rate 
of radic
al 
surgeri
es (RRS
), safet
y
Statisti
cal pow
erTo
 detect
 at leas
t 
35% re
mission
 rate 
differe
nce wit
h powe
r 
80% an
d alpha
 0,05, 
need 5
6 patie
nts for 
every g
roup
Sample
 size 
estima
tion wa
s 165 
patient
s for ev
ery 
group, 
to obta
in 
power 
80% an
d 
alpha 0
,05 
Power 
90%, n
on 
inferio
rity if u
pper lim
it 
was 97
,5% CI 
from 
Hazard
 Ratio (
HR) < 1
,23. 
Final a
nalysis
 if 1.20
0 
event f
ound in
 EPP
Noninf
erioror
ity 
margin
 XELOX
 vs 
FOLFO
X if upp
er 
limit 95
% CI H
R < 
1,30, p
ower 8
0%, 61
0 
patient
s were 
needed
Noninf
eriority
 
margin
 was  1
5%, 
with po
wer 80
% 
and alp
ha 0.05
, 152 
patient
s were 
needed
 
for eac
h group
 (total 
304 pa
tients)
NA
Treatm
ent his
tory
•   Surg
ery
FOLFO
X : 52 (
83,9%)
XELOX
 : 45 (8
0,4%) 
XELOX
 : 138 (
81%)
FOLFO
X: 142 
(83%)
XELOX
: NA
FOLFO
X: NA
XELOX
: 286 (9
1%)
FOLFO
X: 279 
(89%)
NA
XELOX
: NA
FOLFO
X: NA
•   Radi
othera
pyN
A
XELOX
 : 16 (9
%)
FOLFO
X: 27 (1
6%)
XELOX
: NA
FOLFO
X: NA
XELOX
: 84 (27
%)
FOLFO
X: 70 (2
2%)
NA
XELOX
: NA
FOLFO
X: NA
•  Chem
othera
pyF
OLFOX
 : 18 (2
9,9%)
XELOX
 : 13 (2
3,2%)
XELOX
 : 44 (2
6%)
FOLFO
X: 27 (2
6%)
XELOX
: NA
FOLFO
X: NA
XELOX
: NA
FOLFO
X: NA
XELOX
: 30 (19
%)
FOLFO
X: 29 (1
9%)
XELOX
: NA
FOLFO
X: NA
Metast
ases
• 
Liver
FOLFO
X : 46 (
74,2%)
XELOX
 : 46 (8
2,1%)
XELOX
 : 128 (
75%)
FOLFO
X: 141 
(83%)
XELOX
: NA
FOLFO
X: NA
XELOX
: NA
FOLFO
X: NA
NA
XELOX
: 1167 
(74%)
FOLFO
X: 634 
(77%)
• 
Lung
FOLFO
X : 16 (
25,8%)
XELOX
 : 22 (3
9,2%)
XELOX
 : 54 (3
2%)
FOLFO
X: 50 (2
9%)
XELOX
: NA
FOLFO
X: NA
XELOX
: NA
FOLFO
X: NA
NA
XELOX
: 643 (4
1%)
FOLFO
X: 333 
(41%)
• 
Others
FOLFO
X : 19 (
30,6%)
XELOX
: 14 (25
%)
XELOX
 : 71 (4
1%)
FOLFO
X: 46 (2
6%)
XELOX
: NA
FOLFO
X: NA
XELOX
: NA
FOLFO
X: NA
NA
XELOX
: 955 (6
1%)
FOLFO
X: 464 
(56%)
Notes : NA = n
ot
 a
va
ila
bl
e 
= 
no
 d
at
a/
no
t m
en
ti
on
ed
; F
U
 =
 fl
uo
ro
ur
ac
yl
; O
S 
= 
O
ve
ra
ll 
su
rv
iv
al
; T
T
F 
= 
ti
m
e 
to
 tr
ea
tm
en
t f
ai
lu
re
; P
FS
 =
 p
ro
gr
es
si
on
-f
re
e 
su
rv
iv
al
at
au
 T
T
P
 =
 T
im
e 
to
 
progre
ssion;; 
RRS = r
ate of r
adical s
urgerie
s; ORR
 = over
all resp
onse ra
te; the 
eligible
 patien
t popul
ation (
EPP)
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Ta
bl
e 
2.
 E
ff
ic
ac
y 
O
ut
co
m
e 
fr
om
 r
ev
ie
w
ed
 li
te
ra
tu
re
s
Outcom
e
(10)
(12)
(13)
(14)
(15)
(16)
Overall
 Respo
nse 
Rate (O
RR)
FOLFO
X: 27 (4
8,2%)
XELOX
: 27 (43
,5%)
XELOX
: 64 (37
%)
FOLFO
X: 78 (4
6%)
p=0,15
4
XELOX
: 48%
FOLFO
X: 47%
OR=0,9
4 (97,5
% CI = 
0,77 – 
1,15)
XELOX
: 20%
FOLFO
X: 18%
OR=1,1
9 (95%
 CI 
0,79-1,
77)
XELOX
: 39%
FOLFO
X: 46%
Differe
nce bet
ween 
group=
4,7% (
less 
than 15
%)
XELOX
: 50-51
%
FOLFO
X: 54-5
7%
p 
va
lu
e>
 0
,0
5
Overall
 surviv
al (OS)
NA
XELOX
: 18,1 m
onths
FOLFO
X: 20,8
 month
s
p=0,14
5
XELOX
: 19,8 m
onths
FOLFO
X: 19,6
 
month
s
HR=0,9
9 (97,5
% CI 
0,97-1,
20)
XELOX
: 11,9 m
onths
FOLFO
X: 12,6
 month
s
HR=1,0
3 (95%
 CI 
0,87-1,
23)
XELOX
: 19,9 m
onths
FOLFO
X: 20,5
 month
s
HR=1.,
02 (90
% CI 
0,81-1,
30)
XELOX
: 13,8-1
6,0 
month
s
FOLFO
X: 13,8
-15,8 
month
s
p 
va
lu
e>
 0
,0
5
Progre
ssion-f
ree 
surviva
l (PFS)
 
or time
 to tum
or 
progre
ssion (
TTP)
NA FOLFO
X: 7 mo
nths
XELOX
 9 mon
ths
XELOX
: 8,9 m
onths
FOLFO
X: 9,5 m
onths
p=0,15
3
XELOX
: 8,0 m
onths
FOLFO
X: 8,5 m
onths
HR=1,0
4 (97,5
% CI 
0,93-1,
16)
XELOX
: 4,7 m
onths
FOLFO
X: 4,8 m
onths
HR=0,9
7 (0,83
-1,14)
XELOX
: 8,8 m
onths
FOLFO
X: 9,3 m
onths
HR=1,0
0 (90%
 CI 
0,82-1,
22)
XELOX
: 7,4 m
onths
FOLFO
X: 8,8 m
onths
p 
va
lu
e>
 0
,0
5
Median
 durati
on of 
respon
se
NA
XELOX
: 9,2 m
onths
FOLFO
X: 9,4 m
onths
p=0,43
0
XELOX
: 7,5 m
onths
FOLFO
X: 7,6 m
onths
HR=1,0
0 (97,5
% CI 
0,85-1,
18)
XELOX
: 5,6 m
onths
FOLFO
X: 6,2 m
onths
HR=1,1
5 (95%
 CI 
0,79-1,
68)
XELOX
: 10,1 m
onths
FOLFO
X: 8,8 m
onths
HR=0,8
8 (90%
 CI 
0,64-1,
21)
NA
Median
 time to
 
treatm
ent fail
ure 
(TTF)
NA
XELOX
: 6,0 m
onths
FOLFO
X: 6,9 m
onths
p=0,20
4
XELOX
: 5,9 m
onths
FOLFO
X: 6,3 m
onths
HR=1,0
8 (97,5
% CI 
0,97-1,
20)
XELOX
: 4,1 m
onths
FOLFO
X: 4,0 m
onths
HR=0,9
6 (95%
 CI 
0,81-1,
12)
XELOX
: 6,1 m
onths
FOLFO
X: 6,8 m
onths
HR=1,3
2 (90%
 CI 
0,97-1,
78)
NA
Respon
se rate
 to 
surgery
NA
NA
NA
NA
XELOX
: 30 (19
,2%)
FOLFO
X: 34 (2
2,6%)
Nnot a
nalyzed
XELOX
: 3,5%
FOLFO
X: 6,5%
OR=1,9
6 (95%
 CI 
1,18-3,
23)
OR = O
dds Ra
tio, HR
 = Haza
rd Rati
o
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Table 3
. Side e
ffects a
nd toxi
citys G
3/4 rep
orted i
n revie
wed lit
erature
s
Resear
ch
(10)
(12)
(13)
(14)
(15)
(16)
XELOX
FOLFO
XXE
LOX
FOLFO
XXE
LOX
FOLFO
XXE
LOX
FOLFO
XX
ELOX
FOLFO
XXE
LOX
FOLFO
X
Hemat
ology
Anemia
0
1 (1,9%
)5 (
3%)
3 (2%)
NA
NA
NA
NA
3 (2%)
6 (4%)
NA
NA
Tromb
ocytop
enia
2 (3,3%
)1 (1
,9%)
6 (4%)
6 (4%)
46 (7,0%)
20 (3,1%)
10 (3,2
%)7
 (2,3%
)18
 (12%)
8 (5%)
25 (2%
)12
 (2%)
Neutro
penia
6 (9,8%
)4 (7
,4%)
12 (7%
)18
 (11%)
45 (6,9%)
279 (43%)
14 (4,5
%)1
08 (35,1%
)8
 (5%)
70 (47%)
32 (3%
)15
2 (28%
)
Non he
matolo
gy
Nausea
NA
NA
5 (3%)
9 (5%)
30 (4,6%)
33 (5,1%)
62 (19,9%
)8
 (2,6%
)4 
(3%)
9 (6%)
87 (8%
)27
 (5%)
Vomiti
ng
NA
NA
9 (5%)
13 (8%
)34
 (5,2%)
29 (4,5%)
10 (3,2
%)1
0 (3,2%
)3 (
2%)
7 (5%)
61 (6%
)24
 (4%)
Diarrh
ea
5 (8,2%
)7 (1
3%)
24 (14%)
41 (24%)
134 (21%)
73 (11
%)62
 (19,9%
)1
5 (4,9%
)22 (14
%)
10 (7%
)165
 (16%)
55 (10
%)
Constip
ation
NA
NA
1 (<1%
)3 (
2%)
9 (1,4%
)15 (2,3
%)
6 (1,9%
)8 
(2,6%)
NA
NA
NA
NA
Anorex
ia
NA
NA
5 (3%)
4 (2%)
16 (2,4%)
17 (2,6%)
11 (3,5
%)6
 (1,9%
)N
A
NA
NA
NA
Mucosi
tis/sto
matitis
0 (0%)
2 (3,7%
)4 (2
%)
7 (4%)
8 (1,2%
)13 (
2%)
1 (0,3%
)10
 (3,2%
)0 (
0%)
1 (<1%
)11 
(1%)
22 (4%
)
Letargi
a (fatig
ue)
NA
NA
NA
NA
34 (5,2%)
51 (7,9%)
22 (7,1
%)2
7 (8,8%
)NA
NA
212 (20%)
95 (18
%)
Palmar
-planta
r eryth
em 
(PPE)/
hand-fo
ot 
syndro
me
0 (0%)
1 (1,9%
)4 (2
%)
2 (1%)
40 (6,1%)
8 (1,2%
)11 
(3,5%)
2 (0,6%
)5 
(3%)
1 (<1%
)41 
(4%)
3 (1%)
Neurop
athy/
paraes
thesia
15 (24,6%
)10 (18
,5%)
31 (18%)
28 (16%)
55 (8,4%)
48 (7,4%)
1 (0,3%
)9 
(2,9%)
17 (11%)
38 (26%)
107 (10%)
72 (13
%)
Abdom
inal pa
in
1 (1,6%
)0
1 (<1%
)4 (
2%)
36 (5,5%)
25 (3,9%)
14 (4,5
%)1
4 (4,5%
)NA
NA
NA
NA
Asthen
ia
NA
NA
21 (12%)
29 (17%)
26 (4,0%)
22 (3,4%)
10 (3,2
%01
4 (4,5%
)13 
(8%)
14 (9%
)NA
NA
Hyperb
ilirubin
emia
NA
NA
5 (3%)
6 (4%)
NA
NA
NA
NA
NA
NA
NA
NA
Increas
edTran
samina
se NA
NA
3 (2%)
4 (2%)
NA
NA
NA
NA
NA
NA
NA
NA
Fever
NA
NA
0
1 (<1%
)6 (
0,9%)
9 (1,4%
)0
2 (0,6%
)3 
(2%)
4 (3%)
NA
NA
Rash
NA
NA
3 (2%)
1 (<1%
)NA
NA
NA
NA
NA
NA
NA
NA
Epistax
is
NA
NA
0
0
NA
NA
NA
NA
NA
NA
NA
NA
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